Strahlentherapie und Onkologie最新文献

{"title":"The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors : A Turkish Society for Radiation Oncology Central Nervous System Tumors Group Study (TROD 07-008).","authors":"Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Yasemin Bölükbaşı, Yıldız Güney","doi":"10.1007/s00066-024-02338-z","DOIUrl":"https://doi.org/10.1007/s00066-024-02338-z","url":null,"abstract":"<p><strong>Objective: </strong>Intracranial hemangiopericytomas (HPC) are rare tumors. Radiotherapy (RT) is frequently performed after surgery, depending on tumor size, location, and the type of resection. Moreover, RT is preferred as an effective treatment for local recurrence and metastasis. With this multicenter study, we aimed to investigate the effectiveness of postoperative RT in intracranial HPC patients using modern RT techniques.</p><p><strong>Materials and methods: </strong>Patients aged 16 years and older who underwent RT for histologically confirmed intracranial HPC were evaluated retrospectively. Forty-four patients from 17 institutions were included. Demographic characteristics of the patients, pathological findings, and prognostic factors were documented. The Kaplan-Meier method was used for local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS). The interval for survival analyses was calculated according to the end date of RT. Univariate and multivariate analysis methods were used for factors associated with survival and recurrence.</p><p><strong>Results: </strong>Median age was 42 years (16-71) and 70% of the patients were male. The most common initial symptoms were pain (47.7%) and vision problems (15.9%). A supratentorial location was observed in 79.5% of patients. The median maximum tumor dimension was 4.7 (1.6-14) cm. Gross total (GTR) and subtotal resection (STR) were performed in 43.2% and 47.7% of patients, respectively. Adjuvant RT commenced a median of 6 (2-16) weeks after surgery. Postoperative RT was administered using conventionally fractionated intensity-modulated radiotherapy (IMRT) or stereotactic radiosurgery (SRS). A total median dose of 60 (38-66) Gy in a median of 30 (19-33) fractions was used for patients treated with IMRT and a total median dose of 24 (12-25) Gy in a median of 3 (1-5) fractions was used for patients treated with SRS. Local recurrence occurred in 9 patients and locoregional recurrence in 2 patients at a median of 48 months (range 26-143 months) after RT. Reoperation and reirradiation were applied to 5 patients, reirradiation to 4 patients, and reoperation to 2 patients as salvage treatments. Reirradiation was administered at a median dose of 35 (13.5-54) Gy using a median of 5 (1-30) fractions. At a median follow-up of 63 (6-262) months, 5‑year LC was 68.7%, DMFS 87.2%, PFS 60.8%, and OS 95.7%. The presence of residual macroscopic tumor before RT was associated with lower LC (p = 0.01) and shorter PFS (p = 0.04). In the presence of residual tumor before RT, 5‑year LC decreased from 92.9% to 46.7%, while 5‑year PFS decreased from 81.1% to 43.5% compared to patients with GTR. The presence of postoperative tumor was associated with a lower LC rate in Cox regression analyzes (p = 0.02). The hazard ratio was 6.2 (1.2-30). However, the effect of residual disease before RT on OS was not statistically significant.</p><p><strong>Conclusio","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy].","authors":"Katharina Hintelmann, Lukas Böckelmann","doi":"10.1007/s00066-024-02350-3","DOIUrl":"https://doi.org/10.1007/s00066-024-02350-3","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Stereotactic radiotherapy with five fractions vs. robot-assisted prostatectomy: first results of the PACE-A study].","authors":"David Krug, Oliver Blanck, Jürgen Dunst","doi":"10.1007/s00066-024-02326-3","DOIUrl":"https://doi.org/10.1007/s00066-024-02326-3","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In memory of Univ.-Prof. Dr. med. Normann Willich (1946-2024).","authors":"Hans Theodor Eich, Oliver Micke, Michael Baumann, Wilfried Budach, Jürgen Debus, Jürgen Dunst, Rainer Fietkau, Uwe Haverkamp, Mechthild Krause, Franz-Josef Prott, Gabriele Reinartz, Claudia Rübe, Christian Rübe","doi":"10.1007/s00066-024-02349-w","DOIUrl":"https://doi.org/10.1007/s00066-024-02349-w","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity profile and clinical outcomes of stereotactic body radiotherapy with a focal boost without fiducials or perirectal hydrogel spacer for localized prostate cancer.","authors":"Yuichiro Tsurugai, Atsuya Takeda, Naoko Sanuki, Yousuke Aoki, Yuto Kimura, Yohei Oku, Tomohiro Eriguchi, Hiroyuki Yamanaka, Maiko Machida, Tomohiko Matsushita, Shiro Saito","doi":"10.1007/s00066-024-02333-4","DOIUrl":"https://doi.org/10.1007/s00066-024-02333-4","url":null,"abstract":"<p><strong>Purpose: </strong>Whole-prostate dose escalation in stereotactic body radiotherapy (SBRT) for localized prostate cancer (PCa) can improve oncological outcomes, albeit at the cost of increased toxicity. A focal boost to the dominant intraprostatic lesion (DIL) is gaining interest as an alternative approach. Herein, we investigate the safety and efficacy of this approach.</p><p><strong>Methods: </strong>This retrospective study enrolled patients with localized PCa who underwent five-fraction SBRT with a focal boost to the DIL at our institution between May 2016 and August 2021. The prescription doses to the whole prostate were 35 and 36.25 Gy for low- to favorable intermediate-risk PCa and unfavorable intermediate- to high-risk PCa, respectively. The focal boost to the DIL was up to 115-140% of the prescribed dose. None of the patients underwent pretreatment fiducial or perirectal hydrogel spacer placement. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities and oncological outcomes were assessed.</p><p><strong>Results: </strong>Among the 520 patients, 44% were categorized as patients with high-risk PCa. The median follow-up period was 42.9 months. No acute or late grade ≥3 toxicities were observed. Acute and late grade 2 GU toxicities were observed in 22.3 and 6.1%, respectively, while GI toxicities were observed in 2.1 and 0.8% of the patients. The 4‑year relapse-free survival rate was 94.8% among all patients.</p><p><strong>Conclusion: </strong>Our results indicate that SBRT with a focal boost without fiducials or perirectal hydrogel spacer for localized PCa has a promising toxicity profile and oncological outcomes. Longer follow-up studies are necessary to adequately evaluate late toxicities and efficacy.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Long-term results of the ORATOR-study: radiotherapy versus transoral robotic surgery for oropharyngeal cancer].","authors":"Alexander Fabian, Markus Hoffmann","doi":"10.1007/s00066-024-02335-2","DOIUrl":"https://doi.org/10.1007/s00066-024-02335-2","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating through recent evidence on locoregional breast cancer radiotherapy: an initiative by the scientific association of Swiss radiation oncology.","authors":"Pelagia G Tsoutsou, Anna-Lena Eberhardt, Günther Gruber, Guido Henke, Wendy Jeannerret-Sozzi, Claudia Linsenmeier, Kristina Lössl, Maria-Carla Valli, Walter P Weber, Kathrin Zaugg, Khalil Zaman, Daniel Zwahlen","doi":"10.1007/s00066-024-02332-5","DOIUrl":"https://doi.org/10.1007/s00066-024-02332-5","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is the most prevalent cancer in women and radiotherapy (RT) is an integral part of its treatment. High-level evidence guides clinical decisions, but given the abundance of guidelines, a need to navigate within the evidence has been identified by the board of the Scientific Association of Swiss Radiation Oncology (SASRO). A pilot project was initiated aiming to create an overview of recent clinically relevant evidence for BC RT, to make it easily available to (radiation) oncologists and radiation oncologists in training.</p><p><strong>Methods: </strong>A panel of 10 radiation oncology experts for BC RT, one expert in BC surgery, and one expert in BC medical oncology critically reviewed the relevant literature. The panel comprehensively represented different geographical regions of Switzerland as well as university, cantonal, and private institutions. We sought to create a consensual overview of the most relevant questions in BC RT today, accompanied by the most recent and relevant available evidence.</p><p><strong>Results: </strong>From January 2023 to January 2024, the panel met four times to review and work on an initial draft. The final draft was reviewed and accepted by all panelists. We hereby publish this work to make it available to international audiences. After publication, the work will be made available to all SASRO members on the SASRO website. This work is to be updated every 2 years.</p><p><strong>Conclusion: </strong>The identified need was addressed with a successful pilot project and will be further expanded upon in other tumor pathologies.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy.","authors":"Melek Tugce Yilmaz, Pervin Hurmuz, Ezgi Gurlek, Demet Yildiz, Mustafa Cengiz","doi":"10.1007/s00066-024-02339-y","DOIUrl":"https://doi.org/10.1007/s00066-024-02339-y","url":null,"abstract":"<p><strong>Purpose: </strong>The association of cardiac dosimetric parameters with survival in lung cancer patients is well established. However, most research has concentrated on patients undergoing definitive treatment. This study aims to investigate the relationship between cardiac dosimetric parameters and survival in patients receiving postoperative radiotherapy (PORT).</p><p><strong>Methods: </strong>Sixty patients who received PORT between 2011 and 2021 were retrospectively evaluated. The substructures of the heart were delineated on the simulation computed tomography scans of the patients. Univariate and multivariate Cox regression analyses were conducted to investigate the correlation between dosimetric parameters and overall survival. The Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corp., Armonk, NY, USA) was utilized for statistical analyses.</p><p><strong>Results: </strong>Right atrium (RA) maximum dose (Dmax) was the only variable that was significantly associated with a shorter OS. Further receiver operating characteristic (ROC) analysis revealed that the optimum cut-off value for RA Dmax was 43.6 Gy, with a sensitivity of 69% and a specificity of 62%. In addition, inclusion of the upper right paratracheal (2R), lower right paratracheal (4R), left pulmonary ligament (9L), and right hilus (10R) lymphatic stations in the treatment field led to an increase in RA Dmax.</p><p><strong>Conclusion: </strong>The results of this retrospective study show that RA Dmax appears to have an impact on overall survival in patients undergoing PORT. Limiting the RA Dmax dose to below 43.6 Gy and avoiding elective nodal irradiation might potentially enhance survival in this patient cohort.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ampelopsis japonica enhances the effect of radiotherapy in non-small cell lung cancer.","authors":"Zhaohua Liu, Peixia Cui, Qian Wu, Xiao Ji","doi":"10.1007/s00066-024-02322-7","DOIUrl":"https://doi.org/10.1007/s00066-024-02322-7","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is widely used in the clinical treatment of non-small cell lung cancer (NSCLC); however, its effectiveness often proves unsatisfactory. Ampelopsis japonica (AJ) is a traditional Chinese herb with anti-inflammatory and anticancer activities. However, whether AJ could enhance the effect of radiotherapy in NSCLC needs to be further explored.</p><p><strong>Methods: </strong>In vivo, BALB/c nude mice were used for a xenograft tumor model to explore whether AJ could enhance the effect of radiation therapy (RT) in NSCLC. In vitro, human NSCLC cell lines HCC827 and H1299 were used to explore the effect of AJ on the cell proliferation and apoptosis of RT-treated NSCLC. Moreover, bioinformatic analysis was performed to analyze the signaling pathways regulated by AJ.</p><p><strong>Results: </strong>Ampelopsis japonica enhanced the inhibitory effect of RT on NSCLC tumor growth in vivo. Simultaneously, AJ further enhanced the inhibitory effect of RT on NSCLC proliferation and the promoting effect of RT on NSCLC apoptosis. Bioinformatic analysis showed that AJ regulated the PI3K-Akt signaling pathway. We confirmed that AJ decreased the protein levels of the PI3K-Akt signaling pathway. Furthermore, the combination of AJ and RT suppressed activation of the PI3K-Akt signaling pathway.</p><p><strong>Conclusion: </strong>Ampelopsis japonica augmented the inhibitory impact of RT on NSCLC cell proliferation and tumor growth by suppressing the PI3K-Akt signaling pathway.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of kilo- and megavoltage energies in low-dose radiotherapy for painful degenerative musculoskeletal diseases: a systematic review and meta-analysis.","authors":"Aram Kim, Jeanny Kwon, Ji Young Kim, Byoung Hyuck Kim","doi":"10.1007/s00066-024-02329-0","DOIUrl":"https://doi.org/10.1007/s00066-024-02329-0","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the impact of different energy levels on the effectiveness of low-dose radiotherapy (LDRT) for treating painful degenerative musculoskeletal diseases, as comparative efficacy data are currently lacking.</p><p><strong>Methods: </strong>A systematic review was conducted in PubMed, Embase, and the Cochrane Library databases to identify studies with response information on the energy used (kilovoltage [kV] vs. megavoltage [MV]). The primary endpoint was the overall response rate (ORR), and the secondary endpoint was the complete response rate (CRR). Exploratory subgroup analyses included treatment site, study period, study design, country, and dose per fraction.</p><p><strong>Results: </strong>A total of 33 studies involving 12,143 patients were analyzed. Short-term follow-up (up to 6 months) showed a pooled ORR of 64% (95% CI 46-78%) for kV and of 62% (95% CI 54-70%) for MV. Long-term follow-up (at least 12 months) revealed a pooled ORR of 85% (95% CI 65-95%) for kV and of 69% (95% CI 62-75%) for MV. Subgroup analysis indicated no significant differences in ORR for energy level stratified by treatment site and other factors. Regarding dose per fraction (0.5 Gy vs. 1.0 Gy), comparable ORRs were demonstrated between the two energies. No clinical side effects were noted.</p><p><strong>Conclusion: </strong>This meta-analysis suggests that the known effectiveness of LDRT in painful degenerative musculoskeletal disease may not depend on the energy used. Additional studies using standardized evaluation methods are warranted to establish consistency and enhance the comprehensiveness of research. Further research is also needed to explore treatment modality selection considering disease-specific biology.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}